猴痘作为一种新发传染病:对眼科的影响
2022年猴痘疫情构成国际关注的突发公共卫生事件,全球实验室确诊病例超过51257例,其中英国3279例。本文综述猴痘的病原学、传播途径和眼部表现(眶隔前蜂窝织炎、结膜炎、角膜炎),并讨论替考韦马特和三氟胸苷滴眼液等治疗及感染控制措施。
要点
- 猴痘由猴痘病毒(正痘病毒属双链DNA病毒)引起,动物传人后可在人与人之间传播。
- 眼部表现可包括眶隔前蜂窝织炎、结膜炎和角膜炎,临床表现可能类似常见眼科疾病。
- 口服替考韦马特是主要治疗药物,三氟胸苷滴眼液可用于眼部受累,天花疫苗提供一定交叉免疫。
核心结论
- 眼科医生必须了解猴痘及其带来的风险,本次疫情凸显医护人员需实施适当的感染控制措施并熟悉皮肤和眼部病变的识别与治疗。
研究设计与样本
- 本文为综述,总结2022年猴痘疫情的流行病学、病原学、传播途径、眼部表现、治疗和感染控制。
- 截至原文报告时,全球实验室确诊病例超过51257例,其中英国3279例。
主要发现
- 猴痘病毒为痘病毒科正痘病毒属的双链DNA病毒,其他正痘病毒包括天花病毒、牛痘病毒和痘苗病毒,均有显著眼部后遗症。
- 传播由动物宿主(未知,可能为啮齿动物)传至人,继而发生人际传播。
- 近期疫情期间,男同性恋、双性恋或其他男男性行为者中发病率较高。
- 眼部表现可包括眶隔前蜂窝织炎、结膜炎和角膜炎。
关键数值与推荐
- 口服抗病毒药替考韦马特(为治疗天花而研发)是主要治疗药物。
- 三氟胸苷滴眼液可用于眼部受累。
- 天花疫苗提供了一定的交叉免疫。
- 眼部猴痘应由感染病专科医生管理,并咨询眼科医生以提供治疗潜在视力威胁并发症所需的专业知识。
临床怎么用
- 临床诊断可能具有挑战性,因表现可模仿常见眼科疾病,详细病史是识别潜在病例的关键。
- 眼部猴痘应由感染病专科医生管理,并咨询眼科医生。
- 医护人员应实施适当的感染控制措施,并熟悉皮肤和眼部病变的识别与治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The 2022 outbreak of monkeypox is of worldwide significance. There has been a rapid escalation in case numbers despite efforts to contain it and the WHO has declared it a Public Health Emergency of International Concern. To date, over 51 257 laboratory-confirmed cases have been reported, the majority in non-endemic countries, with 3279 in the UK. It is vital for ophthalmologists to understand this disease and the risk it poses. Human monkeypox is a zoonotic disease caused by the monkeypox virus, a double-stranded DNA virus in the Orthopoxvirus genus of the Poxviridae family. Other orthopoxviruses include variola (smallpox), cowpox and vaccinia; all of which have significant ocular sequelae. Transmission occurs from an animal reservoir (unknown, likely rodents) to a human host, leading to secondary human-to-human spread. During the recent outbreak, a higher incidence has been found in gay, bisexual or other men who have sex with men. Clinical diagnosis may be challenging as presentation can mimic common ophthalmic diseases. A thorough history is key to identifying potential cases. Ophthalmic manifestations may include preseptal cellulitis, conjunctivitis and keratitis. The oral antiviral agent tecovirimat, which was developed to treat smallpox, is the mainstay of treatment. Trifluorothymidine (trifluridine) eye-drops can be used for ophthalmic involvement. In addition, smallpox vaccines have provided some cross-immunity. Ocular monkeypox should be managed by infectious diseases specialists, in consultation with ophthalmologists to provide the expertise needed to treat potentially vision-threatening complications. This outbreak highlights the need for healthcare providers to implement appropriate infection control measures and be familiar with the identification and treatment of both cutaneous and ocular disease.
引用
- Milligan AL, Koay SY, Dunning J, et al. Monkeypox as an emerging infectious disease: the ophthalmic implications. Br J Ophthalmol. 2022. PMID: 36216412. doi:10.1136/bjo-2022-322268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。